Tag «PT 977»

Belzutifan

It’s only fair to share… Belzutifan CAS 1672668-24-4 383.34 g·mol−1  C17H12F3NO4S 3-[[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methylsulfonyl-2,3-dihydro-1H-inden-4-yl]oxy]-5-fluorobenzonitrile MK-6482, PT-2977, UNII-7K28NB895L, 7K28NB895L 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile 3-{[(1s,2s,3r)-2,3-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile GTPL11251, PT 2977 [WHO-DD], BDBM373040 FDA APPROVED 8/13/2021, Welireg To treat von Hippel-Lindau disease under certain conditions EMA Drug Information Disease/Condition Treatment of von Hippel-Lindau disease Active Substance 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile Status of Orphan Designation Positive Decision Date 2020-08-21 FDA approves belzutifan for cancers associated with von Hippel-Lindau disease On …